Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2012170438) HUMAN ANTIGEN BINDING PROTEINS THAT BIND TO A COMPLEX COMPRISING β-KLOTHO AND AN FGF RECEPTOR
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2012/170438 International Application No.: PCT/US2012/040941
Publication Date: 13.12.2012 International Filing Date: 05.06.2012
IPC:
C07K 16/28 (2006.01) ,A61P 3/00 (2006.01) ,A61P 3/04 (2006.01) ,A61P 3/10 (2006.01) ,C07K 14/71 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3
Drugs for disorders of the metabolism
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3
Drugs for disorders of the metabolism
04
Anorexiants; Antiobesity agents
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3
Drugs for disorders of the metabolism
08
for glucose homeostasis
10
for hyperglycaemia, e.g. antidiabetics
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
705
Receptors; Cell surface antigens; Cell surface determinants
71
for growth factors; for growth regulators
Applicants:
AMGEN INC. [US/US]; One Amgen Center Drive Thousand Oaks, CA 91320-1799, US (AllExceptUS)
LI, Yang [US/US]; US (UsOnly)
STEVENS, Jennitte [US/US]; US (UsOnly)
KING, Chadwick, Terence [CA/CA]; CA (UsOnly)
FOLTZ, Ian [CA/CA]; CA (UsOnly)
KANNAN, Gunasekaran [US/US]; US (UsOnly)
YIE, Junming [US/US]; US (UsOnly)
HU, Shaw-Fen, Sylvia [US/US]; US (UsOnly)
Inventors:
LI, Yang; US
STEVENS, Jennitte; US
KING, Chadwick, Terence; CA
FOLTZ, Ian; CA
KANNAN, Gunasekaran; US
YIE, Junming; US
HU, Shaw-Fen, Sylvia; US
Agent:
BERNSTEIN, Scott; AMGEN INC. One Amgen Center Drive Patent Operations/MS 28-2-C Thousand Oaks, CA 91320-1799, US
Priority Data:
13/487,06101.06.2012US
61/493,93306.06.2011US
61/501,13324.06.2011US
61/537,99822.09.2011US
Title (EN) HUMAN ANTIGEN BINDING PROTEINS THAT BIND TO A COMPLEX COMPRISING β-KLOTHO AND AN FGF RECEPTOR
(FR) PROTÉINES DE LIAISON À UN ANTIGÈNE HUMAIN QUI SE LIENT À UN COMPLEXE COMPRENANT BÊTA-KLOTHO ET UN RÉCEPTEUR DE FGF
Abstract:
(EN) The present invention provides compositions and methods relating to or derived from antigen binding proteins capable of inducing B-Klotho, and or FGF21-like mediated signaling. In embodiments, the antigen binding proteins specifically bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c. In some embodiments the antigen binding proteins induce FGF21-like signaling. In some embodiments, an antigen binding protein is a fully human, humanized, or chimeric antibodies, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c. Other embodiments provide nucleic acids encoding such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, cells comprising such polynucleotides, methods of making such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, and methods of using such antigen binding proteins, fragments and derivatives thereof, and polypeptides, including methods of treating or diagnosing subjects suffering from type 2 diabetes, obesity, NASH, metabolic syndrome and related disorders or conditions.
(FR) La présente invention concerne des compositions et des procédés associés à ou issus de protéines de liaison à un antigène aptes à induire une signalisation à médiation par B-Klotho et ou de type FGF21. Dans des modes de réalisation, les protéines de liaison à un antigène se lient spécifiquement à un complexe comprenant β-Klotho et au moins un parmi (i) FGFR1c, (ii) FGFR2c et (iii) FGFR3c. Dans certains modes de réalisation, les protéines de liaison à un antigène induisent une signalisation de type FGF21. Dans certains modes de réalisation, une protéine de liaison à un antigène consiste d'anticorps complètement humains, humanisés ou chimériques, de fragments de liaison et de dérivés de tels anticorps et de polypeptides qui se lient spécifiquement à un complexe comprenant β-Klotho et au moins un parmi (i) FGFR1c, (ii) FGFR2c et (iii) FGFR3c. D'autres modes de réalisation concernent des acides nucléiques codant pour de telles protéines de liaison à un antigène et des fragments et dérivés de ceux-ci, et des polypeptides, des cellules comprenant de tels polynucléotides, des procédés de fabrication de telles protéines de liaison à un antigène et des fragments ou dérivés de celles-ci, et des polypeptides, et des procédés d'utilisation de telles protéines de liaison à un antigène, des fragments et dérivés de celles-ci et des polypeptides, comprenant des méthodes de traitement ou de diagnostic de sujets souffrant d'un diabète de type 2, de l'obésité, d'une stéatohépatite non alcoolique (NASH), d'un syndrome métabolique et de troubles ou états associés.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
CA2837473JP2014518640EP2718323AU2012268396